Clinical trials: Psychiatric Disorders Mood
Major Depressive Disorder, Suicide
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Approximately four thousand Canadians die by suicide every year, and suicide is the second leading cause of death in youth and young adults (15-34 years).
- Conditions
- Major Depressive Disorder, Suicide, Treatment Resistant Depression
- Trial name
- Ket-CBT (NCT06480500)
- Testing
- Ketamine hydrochloride, i-CBT (Internet-based Cognitive Behavioural Therapy), Midazolam Hydrochloride
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- University Health Network, Toronto
Bipolar Depression
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant bipolar depression (TRBD).
- Trial name
- NCT03965871
- Testing
- Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine DPI - high dose
- Where
- 12 sites in Poland
- Volunteers
- 88 people
- Sponsor
- Celon Pharma SA
Bipolar Disorder
Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression
The purpose of this study is to assess olanzapine/fluoxetine combination and lamotrigine comparative efficacy, safety and tolerability in acute and longer term treatment of bipolar depression.
- Trial name
- NCT00485771
- Testing
- Olanzapine, Fluoxetine, Lamotrigine
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder, Mania
Taurine as an Anti-Manic Agent: A Double-Blind, Placebo-Controlled Study
The purpose of this study is to determine whether the amino acid taurine has effects on mood stability in bipolar disorder.
- Conditions
- Bipolar Disorder, Mania, Bipolar Depression
- Trial name
- NCT00217165
- Testing
- taurine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mclean Hospital
Major Depression, Major Depression Disorders
Accelerated High-Dose tDCS for Depression
In this study, investigators are testing whether a higher dose of a non-invasive brain stimulation technique, called transcranial direct current stimulation (tDCS), can be safely used in people with depression.
- Trial name
- NCT07226011
- Testing
- Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical University of South Carolina
Depression, Unipolar, Depression, Bipolar
IM Ketamine vs Midazolam for Suicidal ER Patients
Rising US suicide rates and the increased risk of suicide among persons who visit an emergency department (ED) for suicidality make the ED an important site for interventions to prevent suicide.
- Conditions
- Depression, Unipolar, Depression, Bipolar, Suicidal Ideation
- Trial name
- NCT04640636
- Testing
- Ketamine hydrochloride injection, Midazolam injection
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder, Bipolar Disorder
Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy (fNIRS) Study
The purpose of this research is to measure brain activity in individuals with mood disorders and memory problems using a simple, safe, and noninvasive method called functional near-infrared spectroscopy (fNIRS).
- Conditions
- Major Depressive Disorder, Bipolar Disorder, Mild Cognitive Impairment
- Trial name
- NCT06897670
- Testing
- Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels.
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Mayo Clinic
Major Depressive Disorder, Post-Traumatic Stress Disorder
Imaging SV2A in Mood Disorders
This study is designed to examine SV2A density in MDD and PTSD as a correlate of synaptic density, and to determine whether ketamine administration will reverse the synaptic loss in vivo in human subjects.
- Trial name
- NCT02734602
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Yale University
Unipolar Depression
Ketamine Trial for the Treatment of Depression
This study is a Randomized Controlled Trial, investigating the safety and efficacy of administration of ketamine as a potential treatment for depression.
- Trial name
- NCT02401139
- Testing
- Ketamine
- Where
- 2 sites in Australia
- Volunteers
- 10 people
- Sponsor
- The University of New South Wales
Major Depressive Disorder
Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients
Our hypothesis is that using antidepressants during the ECT has a better efficacy and longer time to relapse/recurrence to the ECT without antidepressants.
- Trial name
- NCT04181567
- Testing
- electroconvulsive therapy, agomelatine
- Where
- Taiwan
- Volunteers
- 97 people
- Sponsor
- Kaohsiung Kai-Suan Psychiatric Hospital
Schizophrenia, Schizoaffective Disorder
Evaluation of mHealth for Serious Mental Illness
This study is a waitlist control trial evaluating the acceptability and preliminary efficacy of a smartphone application with people with mental illness.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depressive Disorder, Bipolar Disorder
- Trial name
- NCT04068467
- Testing
- Smartphone App, Waitlist Control
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- University of Washington
Anodal Stimulation tDCS, Major Depression
Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients
Deficient cognitive control (CC) and the use of dysfunctional emotion regulation strategies (ERS) are both central characteristics of major depression.
- Conditions
- Anodal Stimulation tDCS, Major Depression, Cognitive Control, Emotion Regulation
- Trial name
- NCT03039387
- Testing
- anodal transcranial direct current stimulation
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Schizophrenia Disorders, Major Depression
Non-Coding RNAs Gene Expression in Psychiatric Disorders
This study aims to investigate whether specific non-coding RNAs, molecules involved in the regulation of gene expression, are altered in individuals with psychiatric disorders such as schizophrenia, bipolar disorder, major…
- Conditions
- Schizophrenia Disorders, Major Depression, Bipolar Affective Disorders, Obsessive Compulsive Disorder (OCD)
- Trial name
- PsiRNA26 (NCT07649993)
- Testing
- Reverse Transcription Quantitative Polymerase Chain Reaction
- Where
- 5 sites in Italy
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Carmen Concerto
Psychotic Disorders, Mood Disorders
Transcranial Direct Current Stimulation as Treatment for Auditory Hallucinations
The present study aims to examine the efficacy of transcranial direct current stimulation on the severity of auditory hallucinations.
- Conditions
- Psychotic Disorders, Mood Disorders, Personality Disorders, Stress Disorders, Post-Traumatic
- Trial name
- tDCS (NCT01977521)
- Testing
- Eldith DC Stimulator stimulation
- Where
- Netherlands
- Volunteers
- 62 people
- Sponsor
- Iris Sommer
Multiple Sclerosis, Major Depressive Disorder
Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis
The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS.
- Conditions
- Multiple Sclerosis, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT06329414
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Major Depressive Disorder
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment…
- Trial name
- JUNIPER (NCT05536414)
- Testing
- Centanafadine, Escitalopram
- Where
- 62 sites in United States
- Volunteers
- 337 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either…
- Trial name
- TRANSFORM-3 (NCT02422186)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
Motivational Interviews, Bipolar Disorder
Motivational Interviewing in Patients With Bipolar Disorder
Introduction: A poor therapeutic relationship, poor quality of life, impaired functioning, ineffective coping methods, and lack of motivation It is associated with poor adjustment (to symptoms, treatment, and environment) in…
- Trial name
- NCT05428241
- Testing
- Assigned Interventions
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people
- Sponsor
- Pamukkale University
Major Depressive Disorder, Treatment Resistant Depression
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Over 28 million people suffer from current depressive disorder in the European Union. Major depressive disorder (MDD) is one of the most common psychiatric illnesses.
- Trial name
- INTENSIFY MDD (NCT05973851)
- Testing
- Esketamine Nasal Product, Ketamine Hydrochloride, Esketamine hydrochloride
- Where
- 12 sites in Austria, Germany and 4 more
- Volunteers
- 418 people
- Sponsor
- Dr. Inge Winter
Major Depressive Disorder
Optimize and Predict Antidepressant Efficacy for Patient With MDD Using Multi-omics Analysis and AI-predictive Tool
OPADE is a non-profit, observational, multicenter, open-label study aimed at defining personalized treatment for Major Depressive Disorder (MDD).
- Trial name
- OPADE (NCT06550037)
- Where
- Italy
- Volunteers
- 350 people
- Sponsor
- Alessio Fasano
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.